Hormonal therapy in cancer of the breast, XIII. The effect of 9α-fluoro-17α-methyl-Δ4-androsten-3-one-11β,17β-diol (fluoxymesterone) therapy on clinical course and hormonal excretion

✍ Scribed by Albert Segaloff; C. Y. Bowers; Edward L. Rongone; Paul J. Murison; Joseph V. Schlosser

• Publisher: John Wiley and Sons
• Year: 1958
• Tongue: English
• Weight: 263 KB
• Volume: 11
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(195811/12)11:6<1187::aid-cncr2820110613>3.0.co;2-r

✦ Synopsis

HE ANDROGENIC steroids most effective in T the treatment of metastatic breast cancer have all been potent androgens. T o date, the less potent androgens have been less effective.3~4 Hence, when an androgen more potent than testosterone or methyltestosterone became available it was thought important to test it immediately for effectiveness against advanced breast cancer. It is of great interest that although the introduction of an 11shydroxyl group in testosterone reduces its androgenic potency, when this is coupled with the introduction of a 9a-fluoro group of methyltestosterone, it produces an increase in oral androgenic potency.2 From the Endocrine Research Laboratory of the Alton Ochsner Medical Foundation: the D artment of Medicine, Tulane